The stock price of Cue Biopharma Inc (NASDAQ: CUE) has jumped by 9.03 compared to previous close of 1.50. Despite this, the company has seen a fall of -8.17% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-15 that Cue Biopharma (CUE) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Is It Worth Investing in Cue Biopharma Inc (NASDAQ: CUE) Right Now?
Moreover, the 36-month beta value for CUE is 2.04. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CUE is 47.07M and currently, short sellers hold a 8.93% of that float. On April 18, 2024, CUE’s average trading volume was 261.61K shares.
CUE’s Market Performance
The stock of Cue Biopharma Inc (CUE) has seen a -8.17% decrease in the past week, with a -18.09% drop in the past month, and a -45.67% fall in the past quarter. The volatility ratio for the week is 10.76%, and the volatility levels for the past 30 days are at 8.51% for CUE. The simple moving average for the past 20 days is -10.84% for CUE’s stock, with a -37.75% simple moving average for the past 200 days.
Analysts’ Opinion of CUE
Many brokerage firms have already submitted their reports for CUE stocks, with Jefferies repeating the rating for CUE by listing it as a “Buy.” The predicted price for CUE in the upcoming period, according to Jefferies is $6 based on the research report published on March 13, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see CUE reach a price target of $10. The rating they have provided for CUE stocks is “Outperform” according to the report published on June 26th, 2023.
Piper Sandler gave a rating of “Overweight” to CUE, setting the target price at $7 in the report published on November 21st of the previous year.
CUE Trading at -19.16% from the 50-Day Moving Average
After a stumble in the market that brought CUE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.16% of loss for the given period.
Volatility was left at 8.51%, however, over the last 30 days, the volatility rate increased by 10.76%, as shares sank -13.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.51% lower at present.
During the last 5 trading sessions, CUE fell by -8.17%, which changed the moving average for the period of 200-days by -55.34% in comparison to the 20-day moving average, which settled at $1.8158. In addition, Cue Biopharma Inc saw -38.26% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CUE starting from Suri Anish, who purchase 4,000 shares at the price of $2.76 back on Aug 25 ’23. After this action, Suri Anish now owns 135,638 shares of Cue Biopharma Inc, valued at $11,040 using the latest closing price.
PASSERI DANIEL R, the CHIEF EXECUTIVE OFFICER of Cue Biopharma Inc, purchase 3,000 shares at $2.86 during a trade that took place back on Aug 14 ’23, which means that PASSERI DANIEL R is holding 134,578 shares at $8,580 based on the most recent closing price.
Stock Fundamentals for CUE
Current profitability levels for the company are sitting at:
- -9.47 for the present operating margin
- 0.37 for the gross margin
The net margin for Cue Biopharma Inc stands at -9.26. The total capital return value is set at -1.17. Equity return is now at value -98.73, with -66.40 for asset returns.
Based on Cue Biopharma Inc (CUE), the company’s capital structure generated 0.24 points at debt to capital in total, while cash flow to debt ratio is standing at -3.46. The debt to equity ratio resting at 0.31. The interest coverage ratio of the stock is -37.27.
Currently, EBITDA for the company is -48.56 million with net debt to EBITDA at 0.72. When we switch over and look at the enterprise to sales, we see a ratio of 8.28. The receivables turnover for the company is 3.23for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.01.
Conclusion
To wrap up, the performance of Cue Biopharma Inc (CUE) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
